Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.44 Billion CNY | -23.94% |
| 2022 | 7.15 Billion CNY | 12.48% |
| 2021 | 6.36 Billion CNY | 19.38% |
| 2020 | 5.33 Billion CNY | 15.3% |
| 2019 | 4.62 Billion CNY | -3.95% |
| 2018 | 4.81 Billion CNY | 80.32% |
| 2017 | 2.67 Billion CNY | 18.1% |
| 2016 | 2.26 Billion CNY | -1.37% |
| 2015 | 2.29 Billion CNY | 17.02% |
| 2014 | 1.95 Billion CNY | 29.45% |
| 2013 | 1.51 Billion CNY | -14.11% |
| 2012 | 1.76 Billion CNY | -29.37% |
| 2011 | 2.49 Billion CNY | -35.26% |
| 2010 | 3.85 Billion CNY | 73.26% |
| 2009 | 2.22 Billion CNY | 411.03% |
| 2008 | 435.22 Million CNY | 45.37% |
| 2007 | 299.38 Million CNY | 7.77% |
| 2006 | 277.79 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.37 Billion CNY | -0.66% |
| 2024 Q2 | 1.46 Billion CNY | 6.62% |
| 2023 Q3 | 1.35 Billion CNY | -4.36% |
| 2023 Q2 | 1.41 Billion CNY | 8.52% |
| 2023 Q4 | 1.38 Billion CNY | 2.37% |
| 2023 Q1 | 1.3 Billion CNY | -26.26% |
| 2023 FY | 5.44 Billion CNY | -23.94% |
| 2022 Q2 | 1.84 Billion CNY | -3.24% |
| 2022 Q4 | 1.76 Billion CNY | 7.8% |
| 2022 FY | 7.15 Billion CNY | 12.48% |
| 2022 Q1 | 1.91 Billion CNY | 10.18% |
| 2022 Q3 | 1.63 Billion CNY | -11.46% |
| 2021 FY | 6.36 Billion CNY | 19.38% |
| 2021 Q1 | 1.26 Billion CNY | -29.15% |
| 2021 Q2 | 1.84 Billion CNY | 45.57% |
| 2021 Q3 | 1.51 Billion CNY | -17.77% |
| 2021 Q4 | 1.73 Billion CNY | 14.24% |
| 2020 Q3 | 883.27 Million CNY | -29.72% |
| 2020 Q2 | 1.25 Billion CNY | -10.37% |
| 2020 Q1 | 1.4 Billion CNY | -5.61% |
| 2020 FY | 5.33 Billion CNY | 15.3% |
| 2020 Q4 | 1.78 Billion CNY | 102.61% |
| 2019 Q1 | 1.02 Billion CNY | -31.01% |
| 2019 Q2 | 1.1 Billion CNY | 8.08% |
| 2019 Q3 | 1.01 Billion CNY | -8.65% |
| 2019 Q4 | 1.48 Billion CNY | 47.07% |
| 2019 FY | 4.62 Billion CNY | -3.95% |
| 2018 Q1 | 798.06 Million CNY | -9.51% |
| 2018 FY | 4.81 Billion CNY | 80.32% |
| 2018 Q2 | 1.2 Billion CNY | 51.15% |
| 2018 Q3 | 1.12 Billion CNY | -6.85% |
| 2018 Q4 | 1.48 Billion CNY | 31.97% |
| 2017 Q4 | 881.93 Million CNY | 19.47% |
| 2017 Q1 | 455.63 Million CNY | -26.25% |
| 2017 FY | 2.67 Billion CNY | 18.1% |
| 2017 Q2 | 594.4 Million CNY | 30.46% |
| 2017 Q3 | 738.22 Million CNY | 24.2% |
| 2016 Q4 | 617.83 Million CNY | 36.32% |
| 2016 Q2 | 518.54 Million CNY | -22.76% |
| 2016 Q1 | 671.31 Million CNY | -0.6% |
| 2016 FY | 2.26 Billion CNY | -1.37% |
| 2016 Q3 | 453.22 Million CNY | -12.6% |
| 2015 Q4 | 675.39 Million CNY | 63.34% |
| 2015 FY | 2.29 Billion CNY | 17.02% |
| 2015 Q3 | 413.49 Million CNY | -10.64% |
| 2015 Q2 | 462.7 Million CNY | -37.53% |
| 2015 Q1 | 740.7 Million CNY | 41.35% |
| 2014 Q3 | 523.69 Million CNY | -12.5% |
| 2014 Q1 | 312.62 Million CNY | 10.21% |
| 2014 Q4 | 524.02 Million CNY | 0.06% |
| 2014 FY | 1.95 Billion CNY | 29.45% |
| 2014 Q2 | 598.51 Million CNY | 91.45% |
| 2013 Q4 | 283.65 Million CNY | 0.35% |
| 2013 FY | 1.51 Billion CNY | -14.11% |
| 2013 Q1 | 450.65 Million CNY | 6.77% |
| 2013 Q2 | 496.19 Million CNY | 10.1% |
| 2013 Q3 | 282.66 Million CNY | -43.03% |
| 2012 Q3 | 404.97 Million CNY | -9.44% |
| 2012 Q2 | 447.21 Million CNY | -8.27% |
| 2012 FY | 1.76 Billion CNY | -29.37% |
| 2012 Q1 | 487.55 Million CNY | 14.3% |
| 2012 Q4 | 422.07 Million CNY | 4.22% |
| 2011 Q3 | 494.05 Million CNY | -44.83% |
| 2011 Q1 | 678.42 Million CNY | -26.88% |
| 2011 FY | 2.49 Billion CNY | -35.26% |
| 2011 Q4 | 426.54 Million CNY | -13.67% |
| 2011 Q2 | 895.55 Million CNY | 32.01% |
| 2010 Q1 | 810.54 Million CNY | -10.96% |
| 2010 FY | 3.85 Billion CNY | 73.26% |
| 2010 Q4 | 927.86 Million CNY | -16.88% |
| 2010 Q3 | 1.11 Billion CNY | 11.78% |
| 2010 Q2 | 998.69 Million CNY | 23.21% |
| 2009 FY | 2.22 Billion CNY | 411.03% |
| 2009 Q1 | 360.42 Million CNY | 0.0% |
| 2009 Q3 | 533.51 Million CNY | 27.06% |
| 2009 Q4 | 910.3 Million CNY | 70.62% |
| 2009 Q2 | 419.88 Million CNY | 16.5% |
| 2008 FY | 435.22 Million CNY | 45.37% |
| 2007 FY | 299.38 Million CNY | 7.77% |
| 2006 FY | 277.79 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -2001.256% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 48.283% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -9114.478% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -594.694% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -466.485% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -417.132% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -219.097% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -573.035% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -1238.442% |
| SSY Group Limited | 6.46 Billion HKD | 15.742% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -739.828% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -271.003% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 97.986% |